News of the approval of the new Alzheimer’s drug has hit the headlines this week. Lecanemab has been approved by the MHRA, the UK’s regulator, but has been rejected by NICE so it will not be available on the NHS. Lecanemab is part of a new class of drugs that is emerging. It slows the […]

As we mark 7 years of matching volunteers with researchers, we’d like to celebrate some of the highlights from the past year:     Since the service began, there have been over 60,000 enrolments onto studies through Join Dementia Research, that’s an increase of 12,000 in the last year.   Join Dementia Research volunteers played […]

An opinion piece by Professor John O’Brien, NIHR Clinical Research Network National Specialty Lead for Dementias The European Medicines Agency (EMA) has today said no to approving aducanumab – a new drug to treat Alzheimer’s disease. EMA considered that although the drug removed amyloid, a toxic protein that builds up in the brains of people […]

The US Food and Drug Administration (FDA) has this week approved the first drug since 2003 to treat Alzheimer’s disease. Aducanumab, created by US pharmaceutical company Biogen, is an antibody designed to target amyloid, a protein that builds up in the brains of people with early stages of Alzheimer’s disease. Whereas other existing treatments help […]